AADI / Aadi Bioscience: Commercial Stage With Large Market In Label Expansion

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares t more_horizontal

Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is appr more_horizontal

LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing more_horizontal

LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing a more_horizontal

AADI is a commercial stage company with a potential label expansion ahead. It is adequately funded, run by expert management, and has a major catalyst more_horizontal

Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 more_horizontal

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Quan - VP, Business Developm more_horizontal

Company to hold conference call on May 12th at 8:30 am EDT Company to hold conference call on May 12th at 8:30 am EDT more_horizontal